Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

trial (4Q08).

-- ENMD-2076 is an oral selective kinase inhibitor with a unique kinase

profile, including antiproliferative activity and inhibition of

angiogenesis. ENMD-2076 has demonstrated potent antitumor activity as a

single agent in multiple preclinical models, including tumor regression

in breast, colon, and leukemia models without cardiovascular effects.

ENMD-2076 is a unique-in-class compound that inhibits both Aurora A and

growth factor receptors critical to angiogenesis.

-- EntreMed's IND has been accepted by the FDA and a Phase 1 study in

solid tumors is expected to enroll patients in early 2Q08. EntreMed has

been selected for an oral presentation on ENMD-2076 during the American

Association for Cancer Research's "Drugs on the Horizon" symposium to

be held during the AACR annual meeting in April. ENMD-2076 milestones

for 2008 include initiating a Phase 1 trial in solid tumors (1Q08);

initiating a Phase 1 trial in hematological tumors (3Q08/4Q08); and

entering into a development alliance (2H08/1H09).

-- EntreMed plans to discontinue development of 2ME2 (Panzem(R) NCD) for

oncology. Modest antitumor activity has been shown across most of the

clinical studies, yet there is not a clear development path that would

narrow the indications for larger randomized studies. Additional trial

costs, the high doses required for use in oncology, and

manufacturing/process development expenditures would together require

the commitment of a disproportionate amount of resources and limit

clinical development efforts on the remainder of the pipeline. Patients

still on clinical oncology trials, however, will continue to receive

Panzem(R) NCD.

-- EntreMed plans to move 2ME2 forward in rheumatoid arthritis based on

the knowledge gained from the oncolo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... approved for trading in the United States ... expected to commence on September 17, 2014 on the ... to trade on the TSX Venture Exchange under its ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
(Date:9/17/2014)... Cambridge, MA (PRWEB) September 17, 2014 ... and Safety (ACRES) , a multi-stakeholder non-profit collaborative ... and efficiency in clinical research, today announced Phase ... (SASI). , Amir H. Kalali, ... Quintiles and Arti Bajpai, President, Compliance and Quality ...
Breaking Biology Technology:SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... April 30 Dendreon Corporation,(Nasdaq: DNDN ) today announced ... Deutsche Bank 33rd Annual Health Care Conference ... ET, Bank of America Health Care Conference Four ... 11:00 a.m. ET, Rodman & Renshaw 5th Annual Global ...
... 3rd Among US For-Profit Healthcare Companies, EL ... provider of kidney care services, announced it has ... Magazine as one of the Top 125,ranking companies ... awarded to organizations that demonstrate a deep,commitment to ...
... Molecular Quantitative Viral Load Assay, ORANGE COUNTY, ... BEC ) announced today that it has ... virus (HCV) from Siemens Healthcare,Diagnostics. Under the agreement, ... viral load HCV blood test for use on ...
Cached Biology Technology:DaVita Honored for 4th Year as Training Top 125 Recipient 2Beckman Coulter Acquires Rights to Hepatitis C Virus 2
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
(Date:9/17/2014)... very cleverly, some lessons on how to create the ... Shaw, director of the Optical Technology Center at Montana ... the nanoscale, we,ll discover them." , Some of those ... a conference called "The Nature of Light: Light in ... University of Arizona College of Optical Sciences. The conference ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... led a team of Boston University biomedical engineers to ... could help rejuvenate the efficacy of older antibiotics and ... research speaks to new insights into how current antibiotics ... of more effective antibiotics," said James Collins, ...
... Increasing levels of nitrogen deposition associated with industry and ... acidification, reducing plant growth and polluting surface waters, according ... Geoscience . , The study, conducted in the Tatra ... of Montana, Slovak Academy of Sciences, and the U.S. ...
... both physically and mentally, but genetically everyone is ... for decades now. But with population research becoming ... Tim Caulfield is concerned that genetic research could ... Nobel Prize winning geneticist James Watson claimed there ...
Cached Biology News:Biomedical engineers' detective work reveals antibiotic mechanism 2Biomedical engineers' detective work reveals antibiotic mechanism 3Acid soils in Slovakia tell somber tale 2Could genetic research awaken racist attitudes? 2
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: